ClinicalTrials.gg
CompletedNCT03930602Updated Nov 17, 2021

Study to Characterize the Effects of Cytochrome p450 1A2 Inhibition on Systemic Exposure to BMS-986165

A Phase 1 interventional study of BMS-986165 and Fluvoxamine in Healthy, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-11-17.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was May 2019, 7 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

To compare the pharmacokinetic characteristics of BMS-986165 after a single-dose administration alone vs. in combination with fluvoxamine (CYP1A2 inhibitor)

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy participant, as determined by no deviation from normal in medical history, physical examination, (ECGs), and clinical laboratory determinations in the opinion of the investigator.
  • of 18 to 32 kilograms per square meter (kg/m2), inclusive, and body weight ≥ 50 kg, at screening.
  • Normal renal function at screening as evidenced by an estimated (GFR) > 80 milliliter/minute/1.732 meter square calculated with the Chronic Kidney Disease Epidemiology Collaboration formula.

Exclusion criteria

Exclusion Criteria:

  • Any significant acute or chronic medical condition that presents a potential risk to the participant and/or may compromise the objectives of the study,
  • Any major surgery within 4 weeks of study drug administration
  • Participants who currently smoke, as well as those who have stopped smoking less than 6 months prior to dosing on Day 1.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    BMS-986165+Fluvoxamine

    Drug: BMS-986165 · Drug: Fluvoxamine

  • Experimental
    BMS-986165 only

    Drug: BMS-986165

  • Experimental
    Fluvoxamine only

    Drug: Fluvoxamine

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax) of BMS-986165

    Time frame: 10 days

  2. AUC(0-T) of BMS-986165

    Time frame: 10 days

  3. AUC(INF) of BMS-986165

    Time frame: 10 days

Secondary outcomes

  1. Fluvoxamine steady-state plasma concentrations

    Time frame: 10 days

  2. Percentage of participants with Adverse events (AEs)

    Time frame: From screening up to end of drug treatment (Day 13)

  3. Percentage of participants with Serious Adverse events (SAEs) and Death

    Time frame: From screening up to end of drug treatment (Day 13)

  4. Percentage of participants with Adverse events (AEs) leading to discontinutation

    Time frame: From screening up to end of drug treatment (Day 13)

  5. Percentage of participants with clinical significant laboratory abnormalities vital sign measurements and ECGs

    Time frame: From screening up to end of drug treatment (Day 13)

07

Study locations

1 site
  • ICON Plc (PRA Health Sciences)
    Salt Lake City, Utah 84124, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2019 to primary completion in May 2019, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2019
First posted
Apr 29, 2019
StartActual
May 1, 2019
Primary completionActual
May 27, 2019
CompletionActual
May 27, 2019
Last update
Nov 17, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03930602
Responsible party
Sponsor
First posted
Apr 29, 2019
Start date
May 1, 2019
Primary completion
May 27, 2019
Completion
May 27, 2019
Last update
Nov 17, 2021

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Deucravacitinib · Fluvoxamine

Start the discussion